[go: up one dir, main page]

CA2778823A1 - Traitements a la citrulline - Google Patents

Traitements a la citrulline Download PDF

Info

Publication number
CA2778823A1
CA2778823A1 CA2778823A CA2778823A CA2778823A1 CA 2778823 A1 CA2778823 A1 CA 2778823A1 CA 2778823 A CA2778823 A CA 2778823A CA 2778823 A CA2778823 A CA 2778823A CA 2778823 A1 CA2778823 A1 CA 2778823A1
Authority
CA
Canada
Prior art keywords
citrulline
arginine
ornithine
composition
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2778823A
Other languages
English (en)
Inventor
Nicolaas Emile Deutz
Norman Alan Greenberg
Kala Marie Kaspar
Candis Kvamme
Yvette Charlotte Luiking
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA filed Critical Nestec SA
Publication of CA2778823A1 publication Critical patent/CA2778823A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
CA2778823A 2006-04-04 2007-04-02 Traitements a la citrulline Abandoned CA2778823A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US78933006P 2006-04-04 2006-04-04
US60/789,330 2006-04-04
US74749306P 2006-05-17 2006-05-17
US60/747,493 2006-05-17
CA2648126A CA2648126C (fr) 2006-04-04 2007-04-02 Traitements a la citrulline

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2648126A Division CA2648126C (fr) 2006-04-04 2007-04-02 Traitements a la citrulline

Publications (1)

Publication Number Publication Date
CA2778823A1 true CA2778823A1 (fr) 2007-10-11

Family

ID=38461725

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2778823A Abandoned CA2778823A1 (fr) 2006-04-04 2007-04-02 Traitements a la citrulline
CA2648126A Expired - Fee Related CA2648126C (fr) 2006-04-04 2007-04-02 Traitements a la citrulline

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2648126A Expired - Fee Related CA2648126C (fr) 2006-04-04 2007-04-02 Traitements a la citrulline

Country Status (14)

Country Link
US (1) US20090291877A1 (fr)
EP (3) EP2679223A1 (fr)
JP (2) JP2009533342A (fr)
CN (1) CN102935231A (fr)
AU (1) AU2007233371B2 (fr)
BR (1) BRPI0710044A2 (fr)
CA (2) CA2778823A1 (fr)
HK (1) HK1126390A1 (fr)
IL (1) IL194202A0 (fr)
MX (1) MX2008012723A (fr)
PH (1) PH12012501781A1 (fr)
RU (1) RU2444355C2 (fr)
WO (1) WO2007114903A2 (fr)
ZA (1) ZA200809393B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013063533A1 (fr) * 2011-10-26 2013-05-02 Clinical And Herbal Innovations, Inc. Complément alimentaire pour la santé vasculaire
CN112868919A (zh) * 2021-02-25 2021-06-01 新疆农业大学 一种提升公羊精液品质的饲料及其应用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2913885B1 (fr) * 2007-03-22 2012-07-20 Univ Paris Descartes Utilisation de la citrulline pour le traitement des pathologies liees a une augmentation de la carbonylation des proteines
ES2861583T3 (es) 2007-10-10 2021-10-06 Kyowa Hakko Bio Co Ltd Preparación oral de acción rápida que puede aumentar el nivel de arginina en sangre y que comprende citrulina y arginina
ITMI20080567A1 (it) * 2008-04-02 2009-10-03 Androsystems Srl L-citrullina per il trattamento della disfunzione endoteliale e della disfunzione erettile.
SG194345A1 (en) 2008-09-19 2013-11-29 Nestec Sa Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment
RU2011115182A (ru) * 2008-09-19 2012-10-27 Нестек С.А. (Ch) Питательная поддержка для предупреждения и/или ослабления костномозговой токсичности раковой опухоли
US20100179089A1 (en) * 2009-01-13 2010-07-15 Deutz Nicolaas E P Compositions and Methods to Manage the Inflammatory Basis of Chronic Disease Conditions and Maintain an Optimal Immune Response in Elderly
CA2771283A1 (fr) * 2009-08-13 2011-02-17 Nestec S.A. Compositions nutritionnelles comprenant des nucleotides exogenes
FR2970414B1 (fr) 2011-01-14 2013-03-22 Univ Paris Descartes Action preventive de la citrulline sur le developpement spontane des tumeurs
SG193933A1 (en) * 2011-04-18 2013-11-29 Nestec Sa Nutritional compositions having alpha-hica and citrulline
JP2013060406A (ja) * 2011-09-15 2013-04-04 Kyowa Hakko Bio Co Ltd 脳疲労改善用経口剤
EP2821069A4 (fr) * 2012-03-02 2015-06-03 Kyowa Hakko Bio Co Ltd Stimulateur de l'activité alimentaire et/ou de l'activité gastro-intestinale
MX2017015664A (es) * 2015-06-29 2018-04-18 Univ Vanderbilt Administracion intravenosa de citrulina durante cirugia.
JP6357625B2 (ja) * 2015-07-23 2018-07-18 テクノサイエンス株式会社 栄養補助食品用の組成物
KR102396603B1 (ko) 2015-09-16 2022-05-11 원광대학교산학협력단 시트룰린을 유효성분으로 함유하는 간 기능 개선용 조성물
JP2016121194A (ja) * 2016-04-05 2016-07-07 協和発酵バイオ株式会社 脳疲労改善用経口剤
JP2018119017A (ja) * 2018-05-16 2018-08-02 テクノサイエンス株式会社 栄養補助食品用の組成物
JP2023523397A (ja) * 2020-04-29 2023-06-05 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 緩衝組成物及びアミノ酸を含有する栄養製品、並びにかかる栄養製品を使用する方法
JP7609595B2 (ja) 2020-09-30 2025-01-07 花王株式会社 アンモニア代謝促進剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4096254A (en) * 1976-05-10 1978-06-20 Richardson-Merrell Inc. Method of treating the symptoms of menopause and osteoporosis
US5411757A (en) * 1989-11-09 1995-05-02 Buist; Neil R. M. Palatable balanced amino acid-modified diet
DE69228006T2 (de) * 1991-09-27 1999-08-12 Board of Regents, the University of Texas System, Austin, Tex. Parenteral anzuwendende Aminosäuren enthaltende Zubereitungen zur Bekämpfung von Hypotension und verwandten Pathologien
US5780039A (en) 1992-04-23 1998-07-14 Novartis Nutrition Ag Orally-ingestible nutrition compositions having improved palatability
US5356873A (en) * 1992-11-05 1994-10-18 Clintec Nutrition Co. Method for providing nutritional requirements to patients having a chronic inflammation reaction
US5874471A (en) * 1997-02-27 1999-02-23 Waugh; William Howard Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US20020068365A1 (en) 1998-07-28 2002-06-06 Eric H. Kuhrts Controlled release nitric oxide producing agents
AU763000B2 (en) * 1998-10-30 2003-07-10 Nicox S.A. Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use
ATE308254T1 (de) * 1998-12-15 2005-11-15 Nestle Sa Ballaststoffemischung für enterale zusammensetzung
US20020193342A1 (en) 2001-05-09 2002-12-19 Hamman John P. Modifying undesirable tastes
AU2003254282A1 (en) * 2002-08-01 2004-02-23 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
ATE354295T1 (de) * 2002-12-06 2007-03-15 Kyowa Hakko Kogyo Kk Verfahren zur verringerung der bitterkeit von aminosäure
FR2857262B1 (fr) * 2003-07-08 2007-10-05 Biocodex Lab Utilisation de la citrulline dans le cadre de l'insuffisance intestinale
CA2564886A1 (fr) * 2004-04-30 2005-11-17 Pump Formulations, Ltd. Composition nutritionnelle permettant d'ameliorer le stimulus d'un muscle maigre, la croissance, la resistance et la recuperation, creation et prolongement des pompes musculaires intensives, endurance, resistance, performance, taille et resistance, d'assurer un effet transducteur pour l'oxyde nitrique, d'augmenter l'adminis
WO2006002096A2 (fr) * 2004-06-18 2006-01-05 Vivo Therapeutics, Inc. Faibles doses de l-citrulline pour traiter des maladies
US20060046982A1 (en) * 2004-08-26 2006-03-02 Waugh William H Orthomolecular medical use of L-citrulline for capillary endothelial protection and adjacent cell protection in neurodegenerative disease

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013063533A1 (fr) * 2011-10-26 2013-05-02 Clinical And Herbal Innovations, Inc. Complément alimentaire pour la santé vasculaire
CN112868919A (zh) * 2021-02-25 2021-06-01 新疆农业大学 一种提升公羊精液品质的饲料及其应用
CN112868919B (zh) * 2021-02-25 2023-01-17 新疆农业大学 一种提升公羊精液品质的饲料及其应用

Also Published As

Publication number Publication date
EP2004171A2 (fr) 2008-12-24
AU2007233371B2 (en) 2012-11-29
MX2008012723A (es) 2008-10-14
WO2007114903A3 (fr) 2008-02-14
EP2679223A1 (fr) 2014-01-01
CN102935231A (zh) 2013-02-20
AU2007233371A1 (en) 2007-10-11
JP2012197283A (ja) 2012-10-18
US20090291877A1 (en) 2009-11-26
EP2612666A3 (fr) 2013-10-02
WO2007114903A2 (fr) 2007-10-11
RU2008143310A (ru) 2010-05-10
EP2612666A2 (fr) 2013-07-10
JP2009533342A (ja) 2009-09-17
CA2648126A1 (fr) 2007-10-11
RU2444355C2 (ru) 2012-03-10
PH12012501781A1 (en) 2013-06-17
CA2648126C (fr) 2012-12-18
IL194202A0 (en) 2009-09-22
BRPI0710044A2 (pt) 2011-08-02
ZA200809393B (en) 2009-12-30
HK1126390A1 (en) 2009-09-04

Similar Documents

Publication Publication Date Title
CA2648126C (fr) Traitements a la citrulline
RU2356247C2 (ru) Комбинации и композиции, содержащие жирные кислоты и аминокислоты, их применение для предупреждения, замедления прогрессирования или лечения диабета и связанных с диабетом заболеваний и состояний, способ снижения веса тела млекопитающего, набор
CA2784836C (fr) Procede ameliore permettant d'administrer du .beta.-hydroxy-.beta.-methylbutyrate (hmb)
JP2006503105A (ja) ロイシンに富んだ栄養的組成物
EP3021690B1 (fr) Conservation des muscles chez des adultes en surpoids ou obèses pendant un programme de perte de poids
KR20170104575A (ko) 신부전 환자를 치료하기 위한 카복실산 혼합물
US20220240558A1 (en) High-energy food supplement based on inverted sugars and ergogenic products for use in physical activity and method for producing same
JPS63287462A (ja) ペプチド栄養剤
US20120020947A1 (en) Compositions and methods for increasing lean muscle mass after exercise
ES2743955T3 (es) Composiciones que comprenden cinamaldehído y zinc y métodos para utilizar tales composiciones
WO2022240286A1 (fr) Compositions nutritionnelles pour la conservation de la masse musculaire
CN101415414B (zh) 瓜氨酸在制备治疗矫正脓毒症患者中精氨酸缺乏的药物中的用途
JP4163801B2 (ja) アルコール代謝促進作用物
WO2017102965A1 (fr) Compositions contenant de la 3'-o-glucuronide épicatéchine et procédés de fabrication et d'utilisation desdites compositions
call me Mayo Protein+ Creatine+ L-Glutamine
BR112020019737A2 (pt) uso de uma composição
ZA200501922B (en) Leucine-enriched nutritional compositions.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150910